Category: Prostate Cancer

Home / Clinical Research / Prostate Cancer
Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer
Post

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer

By: Melissa Steele-OgusPosted: Thursday, December 10, 2020 Although radical prostatectomy remains one of the primary treatments of localized high-risk prostate cancer, biochemical progression-free survival remains lower than ideal. A study published in the Journal of Clinical Oncology compared the efficacy of radical prostatectomy versus chemohormonal therapy with androgen-deprivation therapy (ADT) plus docetaxel prior to radical prostatectomy. The...

First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer
Post

First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer

By: JNCCN 360 StaffPosted: Wednesday, December 2, 2020 On December 1, the U.S. Food and Drug Administration approved the radioactive diagnostic agent gallium 68 PSMA-11 (Ga 68 PSMA-11), the first drug for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate...

BASKET Study – Covers multiple solid tumor cancer types
Post

BASKET Study – Covers multiple solid tumor cancer types

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the drug is expected to work against cancer. This study will enroll...